Financial Data and Key Metrics Changes - Elanco reported $1.14 billion in revenue for Q4 2025, a 12% increase year-over-year, with 9% organic constant currency growth driven primarily by volume increases [23][24] - Full-year revenue reached $4.715 billion, representing a 6% growth, with Adjusted EBITDA of $901 million and Adjusted EPS of $0.94, compared to $0.91 in 2024 [26][27] - The net leverage ratio improved to 3.6 times at year-end, with expectations to reduce it to 3.1-3.3 times in 2026 [6][28] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue grew 10% in Q4, driven by innovation products like Credelio Quattro and Zenrelia, while international pet health grew 8% [23][24][9] - U.S. Farm Animal business achieved a 17% growth in Q4, with strong contributions from Experior and Pradalex, while international farm animal grew 4% [24][9] - Innovation revenue for 2025 was $892 million, with expectations to reach $1.15 billion in 2026 [5][10] Market Data and Key Metrics Changes - The U.S. broad-spectrum parasiticide market grew 30% year-over-year, with Credelio Quattro gaining significant market share [12][11] - Zenrelia achieved over 30% market share in Japan and 40% in Brazil, indicating strong international performance [15][42] - The overall animal health market is projected to add $20 billion in value over the next decade, with Elanco positioned to capitalize on this growth [34] Company Strategy and Development Direction - Elanco's strategy focuses on growth, innovation, and cash management, with a commitment to introducing new products and enhancing operational efficiency [5][21] - The company is expanding its leadership in the dairy industry through the acquisition of AHV International, which will enhance its portfolio and market presence [20][21] - Elanco Ascend, a productivity initiative, aims to drive efficiencies and margin enhancements starting in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elanco's trajectory, highlighting strong momentum and a commitment to transforming animal care [33][38] - The company anticipates sustainable revenue growth driven by innovation and strategic pricing, despite competitive pressures [31][36] - Management acknowledged the importance of adapting to changing consumer behaviors in both pet health and farm animal sectors [35][37] Other Important Information - Adjusted gross margin increased to 51.2% in Q4, driven by price and volume increases, while operating expenses grew by 10% to support strategic investments [24][25] - The effective tax rate for 2025 was 21.8%, reflecting a year-over-year increase due to non-recurring tax credits recognized in 2024 [27] Q&A Session Summary Question: Insights on Zenrelia's international share gains - Management noted that Zenrelia's efficacy is increasingly recognized, leading to significant share gains in international markets like Japan and Brazil, with expectations for continued growth in the U.S. [41][42][44] Question: Impact of Covetrus and MWI merger on Elanco - Management emphasized strong relationships with distributors and the value they add, indicating confidence in maintaining competitive advantages despite market changes [48][49] Question: Clarification on pricing strategy for 2026 - Management confirmed expectations for accelerating price growth in 2026, driven by the value of new innovations and a comprehensive portfolio [54][56] Question: Stocking dynamics and competitive positioning in parasiticides - Management reported strong dispensing demand with no significant stocking issues, indicating a solid position in the parasiticides market [65][66] Question: Timeline for Zenrelia label update in the U.S. - Management is in constructive dialogue with the FDA regarding the label update, with confidence in achieving alignment with international standards [68][70]